Short-read Next-gen Sequencing Archives

20 10, 2025

Technote: GUIDE-Seq/iGuide for CRISPR On/Off Target Analysis

webmaster2025-12-11T18:39:42+00:00

This guide provides an in-depth look at GUIDE-Seq/iGuide, a key technique for assessing CRISPR-Cas9 on- and off-target effects in gene and cell therapy development. It explains how the method informs the selection of gRNAs, nucleases, and CRISPR conditions to maximize specificity and safety. Readers will also gain insights into the full workflow, from Cas9 cleavage to NGS analysis, supported by Avance Biosciences’ expertise as a licensed GUIDE-Seq service provider...

Technote: GUIDE-Seq/iGuide for CRISPR On/Off Target Analysiswebmaster2025-12-11T18:39:42+00:00

20 10, 2025

Technote: NGS for Biologics Development Support

webmaster2025-12-11T18:40:13+00:00

Explore the power of Next Generation Sequencing (NGS) for biologics development support with our latest whitepaper. Avance Biosciences is at the forefront of NGS testing, offering tailored solutions to support drug development initiatives and GMP manufacturing activities. Delve into real-world case studies, including CRISPR indel amplicon sequencing and insertion site studies, showcasing our expertise in assay development and validation...

Technote: NGS for Biologics Development Supportwebmaster2025-12-11T18:40:13+00:00

17 10, 2025

Poster Presentation: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq
Gallery

Poster Presentation: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq

webmaster2025-10-22T20:51:05+00:00

Genome editing offers unprecedented precision, but off-target effects remain a key safety concern. GUIDE-Seq provides a high-throughput, genome-wide method to map CRISPR-Cas activity in living cells, enabling researchers to assess specificity and ensure safer gene-editing therapies...

Poster Presentation: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seqwebmaster2025-10-22T20:51:05+00:00

5 08, 2025

Case Study: Quantifying In Vivo Gene Editing in Preclinical Tissues via NGS Amplicon-Seq
Gallery

Case Study: Quantifying In Vivo Gene Editing in Preclinical Tissues via NGS Amplicon-Seq

webmaster2025-10-22T20:51:20+00:00

To support IND-enabling studies, a biotech company needed precise measurement of in vivo gene-editing efficiency in preclinical rat tissues. Avance Biosciences delivered a fully validated NGS amplicon sequencing assay capable of detecting edits as low as 1%, enabling accurate quantification across multiple tissues and guiding data-driven development decisions.

Case Study: Quantifying In Vivo Gene Editing in Preclinical Tissues via NGS Amplicon-Seqwebmaster2025-10-22T20:51:20+00:00

5 08, 2025

Case Study: Ensuring Plasmid Sequence Fidelity and Purity by NGS for IND-Enabling Drug Substance Release
Gallery

Case Study: Ensuring Plasmid Sequence Fidelity and Purity by NGS for IND-Enabling Drug Substance Release

webmaster2025-10-22T20:51:27+00:00

When a gene therapy company needed to verify plasmid identity, purity, and integrity for an IND submission, Avance Biosciences delivered a validated NGS-based solution. The assay enabled low-level variant detection and trace contaminant analysis, supporting FDA compliance and lot release.

Case Study: Ensuring Plasmid Sequence Fidelity and Purity by NGS for IND-Enabling Drug Substance Releasewebmaster2025-10-22T20:51:27+00:00

Why We Brought PacBio HiFi Online at Avance: The Accuracy Needed for Plasmid QC

Why Cell Therapy Developers Are Moving From Sanger to NGS for Identity & Purity Testing

FDA’s New Plausible Mechanism Pathway: How It Compares to Existing Approval Routes

Advanced Therapies USA – 2025

AAPS PharmSci 360 Meeting – 2025

World ADC Conference – 2025